Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Nasopharyngeal Cancer-Pipeline Review, H1 2015

Nasopharyngeal Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Nasopharyngeal Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Nasopharyngeal Cancer-Pipeline Review, H1 2015', provides an overview of the Nasopharyngeal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Nasopharyngeal Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Nasopharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Nasopharyngeal Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Nasopharyngeal Cancer-Overview 10

Pipeline Products for Nasopharyngeal Cancer-Comparative Analysis 11

Nasopharyngeal Cancer-Therapeutics under Development by Companies 12

Nasopharyngeal Cancer-Therapeutics under Investigation by Universities/Institutes 14

Nasopharyngeal Cancer-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Nasopharyngeal Cancer-Products under Development by Companies 18

Nasopharyngeal Cancer-Products under Investigation by Universities/Institutes 19

Nasopharyngeal Cancer-Companies Involved in Therapeutics Development 20

Ambrx, Inc. 20

AVEO Pharmaceuticals, Inc. 21

BioDiem Ltd 22

Celgene Corporation 23

Cyclacel Pharmaceuticals, Inc. 24

F. Hoffmann-La Roche Ltd. 25

GlaxoSmithKline plc 26

Merck & Co., Inc. 27

Otsuka Holdings Co., Ltd. 28

Pharmacyclics, Inc. 29

Theravectys S.A. 30

Zhejiang BetaPharma Co., Ltd. 31

Nasopharyngeal Cancer-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Combination Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

abexinostat hydrochloride-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

azacitidine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Cell Therapy 2 for Oncology and Infectious Disease-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Cell Therapy for Metastatic Nasopharyngeal Carcinoma and Colorectal Cancer-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Cell Therapy for Nasopharingeal Carcinoma-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Cell Therapy to Target Latent Membrane Protein-2 for Oncology-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Cell Therapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Cell Therapy to Target LMP-1 and LMP-2 for Oncology-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Dendritic Cells + Cytokine Induced Killer Cells-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

EBV-nRNA-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ficlatuzumab-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Gene Therapy to Activate p53 for Oncology-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

GSK-2849330-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

icotinib hydrochloride-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

MK-2206-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

NEO-212-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

OPB-51602-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

RO-5203280-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

seliciclib-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecules for Nasopharyngeal and Colon Cancers-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Stem Cell Therapy for Oncology-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Vaccine for EBV Associated Nasopharyngeal Cancer-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Vaccine to Target EBV for Nasopharyngeal Carcinoma-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Nasopharyngeal Cancer-Recent Pipeline Updates 75

Nasopharyngeal Cancer-Dormant Projects 80

Nasopharyngeal Cancer-Product Development Milestones 81

Featured News & Press Releases 81

Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 81

May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 82

Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 82

Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 83

Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 84

Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 84

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 87

Disclaimer 87

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H1 2015 10

Number of Products under Development for Nasopharyngeal Cancer-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Investigation by Universities/Institutes, H1 2015 19

Nasopharyngeal Cancer-Pipeline by Ambrx, Inc., H1 2015 20

Nasopharyngeal Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 21

Nasopharyngeal Cancer-Pipeline by BioDiem Ltd, H1 2015 22

Nasopharyngeal Cancer-Pipeline by Celgene Corporation, H1 2015 23

Nasopharyngeal Cancer-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 24

Nasopharyngeal Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 25

Nasopharyngeal Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 26

Nasopharyngeal Cancer-Pipeline by Merck & Co., Inc., H1 2015 27

Nasopharyngeal Cancer-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 28

Nasopharyngeal Cancer-Pipeline by Pharmacyclics, Inc., H1 2015 29

Nasopharyngeal Cancer-Pipeline by Theravectys S.A., H1 2015 30

Nasopharyngeal Cancer-Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015 31

Assessment by Monotherapy Products, H1 2015 32

Assessment by Combination Products, H1 2015 33

Number of Products by Stage and Target, H1 2015 35

Number of Products by Stage and Mechanism of Action, H1 2015 37

Number of Products by Stage and Route of Administration, H1 2015 39

Number of Products by Stage and Molecule Type, H1 2015 41

Nasopharyngeal Cancer Therapeutics-Recent Pipeline Updates, H1 2015 75

Nasopharyngeal Cancer-Dormant Projects, H1 2015 80

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, H1 2015 10

Number of Products under Development for Nasopharyngeal Cancer-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Top 10 Targets, H1 2015 34

Number of Products by Stage and Top 10 Targets, H1 2015 34

Number of Products by Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Top 10 Routes of Administration, H1 2015 38

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38

Number of Products by Top 10 Molecule Types, H1 2015 40

Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ambrx, Inc.

AVEO Pharmaceuticals, Inc.

BioDiem Ltd

Celgene Corporation

Cyclacel Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Merck & Co., Inc.

Otsuka Holdings Co., Ltd.

Pharmacyclics, Inc.

Theravectys S.A.

Nasopharyngeal Cancer Therapeutic Products under Development, Key Players in Nasopharyngeal Cancer Therapeutics, Nasopharyngeal Cancer Pipeline Overview, Nasopharyngeal Cancer Pipeline, Nasopharyngeal Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com